Agios Pharmaceuticals (AGIO) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2025 value amounting to -$108.0 million.
- Agios Pharmaceuticals' Income towards Parent Company fell 1193.08% to -$108.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$414.6 million, marking a year-over-year decrease of 16182.69%. This contributed to the annual value of -$412.8 million for FY2025, which is 16126.85% down from last year.
- According to the latest figures from Q4 2025, Agios Pharmaceuticals' Income towards Parent Company is -$108.0 million, which was down 1193.08% from -$103.4 million recorded in Q3 2025.
- In the past 5 years, Agios Pharmaceuticals' Income towards Parent Company registered a high of $2.0 billion during Q1 2021, and its lowest value of -$112.5 million during Q2 2025.
- For the 4-year period, Agios Pharmaceuticals' Income towards Parent Company averaged around $116.4 million, with its median value being -$88.0 million (2023).
- Per our database at Business Quant, Agios Pharmaceuticals' Income towards Parent Company soared by 438287.33% in 2021 and then crashed by 11091.16% in 2025.
- Agios Pharmaceuticals' Income towards Parent Company (Quarter) stood at $4.0 million in 2021, then crashed by 2524.56% to -$95.9 million in 2023, then dropped by 0.61% to -$96.5 million in 2024, then decreased by 11.93% to -$108.0 million in 2025.
- Its Income towards Parent Company stands at -$108.0 million for Q4 2025, versus -$103.4 million for Q3 2025 and -$112.5 million for Q2 2025.